Welcome to our dedicated page for Prelude Therapeutics news (Ticker: PRLD), a resource for investors and traders seeking the latest updates and insights on Prelude Therapeutics stock.
Prelude Therapeutics Inc (PRLD) is a clinical-stage biopharmaceutical company advancing precision oncology through targeted small molecule therapies. This dedicated news hub provides stakeholders with verified updates on clinical developments, research breakthroughs, and corporate milestones.
Find comprehensive coverage of PRLD's innovative pipeline including SMARCA2 protein degraders and selective CDK9 inhibitors, alongside strategic collaborations shaping cancer treatment paradigms. Our curated news selection prioritizes factual reporting on trial progress, regulatory communications, and partnership announcements without speculative content.
Key updates include phase 1 clinical data, scientific conference presentations, and manufacturing developments. Bookmark this page for efficient tracking of PRLD's progress in addressing high-unmet medical needs through molecularly targeted approaches.
Prelude Therapeutics, a clinical-stage precision oncology company (Nasdaq: PRLD), announced participation in three healthcare investment conferences. On May 2, CEO Kris Vaddi will engage in a fireside chat at the H. C. Wainwright BioConnect Investor Conference at Nasdaq. The Bank of America Securities 2023 Healthcare Conference will feature Dr. Jane Huang and CFO Laurent Chardonnet in one-on-one meetings on May 10 and 11, with Dr. Huang presenting a fireside chat on May 10 at 4:20 p.m. PT. Lastly, during the JMP Securities Life Sciences Conference on May 15 and 16, Dr. Vaddi and Mr. Chardonnet will hold one-on-one meetings, with Dr. Vaddi participating in a fireside chat on May 15 at noon ET. Prelude's pipeline includes four promising drug candidates targeting key cancer pathways.
Prelude Therapeutics (Nasdaq: PRLD), a clinical-stage precision oncology company, announced the presentation of eight abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2023, occurring from April 14-19 in Orlando, Florida. The research highlights progress in their pipeline, including two clinical abstracts on compounds PRT1419 and PRT2527, which target specific cancer pathways in advanced tumors. Jane Huang, President and CMO, noted the supportive safety and pharmacokinetic profiles for further development in hematological cancers. Additionally, preclinical data on the SMARCA2 degrader program will be presented, alongside favorable data on other candidates such as PRT3645 and PRT3789. This showcases Prelude's commitment to innovative treatment options for cancer patients.
Prelude Therapeutics (Nasdaq: PRLD) reported significant advancements in its clinical pipeline during 2022, highlighting four differentiated compounds in Phase 1 trials. The company aims to present initial data from its PRT2527 and PRT1419 programs at the upcoming AACR Annual Meeting. As of December 31, 2022, Prelude's cash reserves stood at $201.7 million, sufficient to fund operations through Q4 2024. Research and development expenses increased to $92.9 million, while general and administrative costs rose to $30.7 million. The company posted a net loss of $115.4 million for the fiscal year, slightly higher than the previous year.
FAQ
What is the current stock price of Prelude Therapeutics (PRLD)?
What is the market cap of Prelude Therapeutics (PRLD)?
